MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Neurology, Psychology, Mental Health, CNS, Pain & TBI Companies _ Sleep Medicine
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)*
Organization & Developments: Harmony Biosciences
Parents
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)*
Children
*Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients living with rare neurological disorders
*The company develops and commercializes therapies for patients with rare neurological disorders.
*The Company’s product WAKIX (pitolisant), is a molecule with a novel mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors
2021: Our First Look At Harmony Biosciences
2022: Harmony Biosciences Holdings, Inc. 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2022: Harmony Biosciences: Steady Revenue Generator Looking For A Future_seekingalpha.com
2022: Harmony Biosciences: Strong Growth At A Reasonable Price_seekingalpha.com
2022: Harmony Biosciences: Up 40% Since My Last Coverage, Waiting For Another Opportunity_ seekingalpha.com
2023: Harmony (HRMY) Stock Tanks On Study Miss For Narcolepsy Drug
2023: Harmony Biosciences: 4 Problems With Investing (Rating Downgrade)_ seekingalpha.com
2024: HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
2024: Harmony Biosciences: Advancing An Expanded Pipeline
2025: Harmony Biosciences Revenue Surges 23% to $714M, Sets Ambitious $820M Target for 2025
2025: Harmony Biosciences: Don't Sleep On This Enterprising, Profitable Biotech_seekingalpha.com
2025: Harmony Biosciences: If It Ain't Broke
2025: Harmony Biosciences: Reiterating Buy Ahead Of Data Catalyst For Cannabinoid Drug
2025: Harmony halts genetic disease program following phase 3 fragile X failure
Jumps
Finance & Acquisitions: Harmony Biosciences
Key People: Harmony Biosciences